denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Description:
This session will focus on recent advances in the clinical understanding and treatment of myeloproliferative neoplasms with emphasis on essential thrombocythemia, polycythemia vera, myelofibrosis and Myelodysplastic/Myeloproliferative (MDS/MPN) Overlap Syndromes.
Dr. John Mascarenhas will provide an update on myelofibrosis risk stratification, including the recent integration of molecular and cytogenetic markers. He will also briefly review the current status of JAK2 inhibitor therapy in the treatment of myelofibrosis, as well as discuss novel therapeutic approaches including combination therapy and hematopoietic stem cell transplantation.
Dr. Deepti Radia will present an overview on symptom evaluation in myeloproliferative neoplasms with a focus on current therapeutic approaches in the management of patients with essential thrombocythemia and polycythemia vera.
Dr. Eric Padron will outline recent discoveries in understanding the molecular pathogenesis of adult MDS/MPN overlap syndromes with a focus on Chronic Myelomonocytic Leukemia. Observations in the laboratory that are anticipated to rapidly translate to the clinic will be emphasized. An overview of the disease specific symptomatology and prognosis will provide a framework for a discussion regarding therapeutic decisions in MDS/MPNs.